Insider Buying: Quince Therapeutics, Inc. (NASDAQ:QNCX) President Buys 48,387 Shares of Stock

Quince Therapeutics, Inc. (NASDAQ:QNCX) President Charles S. Ryan acquired 48,387 shares of the stock in a transaction on Tuesday, August 20th. The shares were acquired at an average price of $0.65 per share, with a total value of $31,451.55. Following the transaction, the president now directly owns 122,461 shares of the company’s stock, valued at $79,599.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Quince Therapeutics Stock Performance

NASDAQ:QNCX remained flat at $0.64 during midday trading on Thursday. The company had a trading volume of 315,997 shares, compared to its average volume of 116,631. The stock has a market cap of $27.70 million, a price-to-earnings ratio of -0.84 and a beta of 0.94. The firm has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.94. Quince Therapeutics, Inc. has a one year low of $0.51 and a one year high of $1.43. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.16 and a quick ratio of 7.16.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.